Marketing of Phenylbutazone and Analgin in the Country

3200. SHRI CHITTA BASU : Will the Minister to HEALTH AND FAMILY WELFARE be pleased to state :

(a) Whether it is a fact that combination of Phenylbutazone and Analgin is allowed for marketing in the country ;

(b) if so, tha dstails of the composition allowed and indication for which it has been cleared for marketing;

(c) whether it is a fact that both these drugs are hazardous and have been withdrawn in a number of countries;

(d) if so, the names of thos[e] countries;

(e) what are the names of five majjor selling brands of this combination being marketed along with names of manufacturers; and

(f) what are the dangerous ef fects noted of these drugs in other countries and what corrective steps have been taken by Government in this regard ?

THE MINISTER OF TEXTILES AND THE MINISTER OF HEALTH AND FAMILY WEL-E (SHRI RAM NIWAS MIR-DHA) : fa) Yes. Sir.

(b) and (e) Esgipyrin, a brand of fixed dose combination of Phenylbutazone (150 mg.), Analgin (150 mg.), Lidocafine (10 mg.) per ml. injection is marketed by M/s SG Pharmaceuticals, Baroda for treatment of rheumatoid arthritis. A statement showing the names of 5 brands of combinations containing Phenylbutazone and Analgin together with the names of their manufacturers is enclosed. *(See* below).

(c) and (d) While Analgin and Phenylbutazone are withdrawn in certain countries, they continue to be marketed in a number of countries. Analgin is reported to be withdrawn in Australia, Norway, USA, Denmark, Bangladesh, Sweden, Canada, Jordan, Singapore and Greece. Phenyl butanone is reported to be withdrawn in Norway, Jordan and United Arab Emirates. The countries have withdrawn these drugs on the ground of adverse reaction to blood.

(f) Reasons which weighed with the countries deciding to withdraw Analgin and Phenylbutazone are based on the consideration of benefit and risk ratio and that these drugs could cause adversed reactions to blood. However, tne recent studies, both retrospective and prospective have ruled out the possibility of "Extra risk" of blood disorders due to Analgin or Phenylbutazone, compared to that of other Analgesics/Non-Steroidal Anti-Inflammatory Drugs.

Statement

Names of five brands of combinations containing Phenylbutazone and Analgin ogether with the names of their manufacturers

	Name of the Product	N :me of the manufacturer
1	Bunrin-D Inj	M/s. Themis Pharmaceuticals, Bombay.
'..	Esgipyrin Inj.	M/s. SG Pharmaceuticals, Baroda.
3.	Baripyrin Forte Tabs.	*Mis.* Sanitex a division of Barooharm Chemicals, Baroda.
4.	Dicipyrin-N Inj.	M/s. DCI Pharmaceuticals Margao, Goa.
5.	Dexabutazone Tablets	M/s. Stadchem of India, Faridabad.